BGB-3245, a second-generation B-RAF inhibitor, has shown to inhibit tumor cell lines harboring non-V600 B-RAF mutations and was also active toward B-RAF/MAP-ERK kinase (MEK) inhibitor-resistant tumors [315]. This evidence concerns the gene MAP2K7 and neoplasm.